Please check your internet connection and try again.
# Valethamate bromide
## Overview
Valethamate bromide is a quaternary ammonium anticholinergic agent with additional musculotropic (spasmolytic) properties. It acts by antagonizing muscarinic receptors and exerting a direct inhibitory effect on smooth muscle fibers.
## Primary Indications
* Adjunct in the management of smooth muscle spasms (e.g., gastrointestinal or biliary).
* Historically utilized in obstetrics to facilitate cervical dilation during the first stage of labor (note: efficacy and safety in this setting are inconsistently supported by modern evidence).
## Adult Dosing
* **Oral:** 10–20 mg three to four times daily.
* **Intramuscular/Intravenous:** 8–16 mg; may be repeated as necessary depending on clinical response.
* **Maximum Dose:** Typically not to exceed 80–100 mg per 24 hours, depending on regional product labeling and clinical indication.
## Pediatric Dosing
* **Data is limited.** Generally not recommended for routine pediatric use. If required by clinical protocol, dosing is weight-based (e.g., 0.1–0.2 mg/kg per dose), typically under specialist supervision.
## Dose Adjustments
* **Renal Impairment:** Reduce dose or increase dosing interval due to potential for accumulation of the quaternary ammonium salt.
* **Hepatic Impairment:** No specific guidelines; use with caution.
* **Geriatric:** Increased risk of anticholinergic side effects (delirium, urinary retention, sedation). Start with the lowest effective dose.
## Contraindications
* Hypersensitivity to the drug.
* Glaucoma (narrow-angle).
* Prostatic hypertrophy or bladder neck obstruction.
* Pyloric stenosis or paralytic ileus.
* Myasthenia gravis.
* Tachycardia or unstable cardiovascular status.
## Adverse Effects
* **Common:** Dry mouth, blurred vision, photophobia, constipation, urinary retention, and tachycardia.
* **Severe:** Confusion/delirium (especially in elderly), palpitations, arrhythmias, and acute angle-closure glaucoma.
## Key Drug Interactions
* **Other Anticholinergics:** Additive toxicity (e.g., antihistamines, tricyclic antidepressants, antipsychotics).
* **Potassium Chloride:** Increased risk of gastrointestinal mucosal injury with oral solid dosage forms.
* **Pilocarpine:** Antagonism of effects.
## Monitoring
* Monitor heart rate and rhythm.
* Assess for urinary output/retention.
* Evaluate for gastrointestinal transit changes.
* Monitor for signs of anticholinergic toxicity (the "mad as a hatter, blind as a bat" syndrome).
## Clinical Pearls
* Valethamate is less selective than modern anticholinergics; peripheral side effects are common.
* Due to the quaternary ammonium structure, it does not readily cross the blood-brain barrier at therapeutic doses compared to tertiary amines (like atropine), theoretically reducing CNS effects; however, toxic doses can still cause central excitation or depression.
* Clinical practice varies significantly by region; refer to your local hospital formulary or regional clinical guidelines for specific indications and dosing restrictions.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always verify specific dosing, safety, and contraindications by consulting current FDA or local regulatory-approved prescribing information, your facility’s clinical guidelines, and a licensed pharmacist before administering any medication.
